Tumor-Infiltrating Lymphocyte (Til) Therapy Market Size, Share Global Analysis Report, 2025 – 2034

Industry Insights

[221+ Pages Report] According to Facts & Factors, the global tumor-infiltrating lymphocyte (TIL) therapy market size was valued at USD 289.56 million in 2024 and is predicted to surpass USD 3,582.19 million by the end of 2034. The tumor-infiltrating lymphocyte (TIL) therapy industry is expected to grow by a CAGR of 28.60% between 2025 and 2034.

Tumor-Infiltrating Lymphocyte (TIL) Therapy Market: Overview

Tumor-infiltrating lymphocyte therapy refers to a treatment used in the management of cancers, particularly solid tumors. TILs work by extracting the patient's sample. Later, these immune cells are extracted from these tissues and multiplied in the laboratory.

Then, the patient undergoes chemotherapy to reduce the existing immune cells and make space for TILs. These cells are then reinfused into the patient's body. It is a highly personalized therapy customized according to the patient's requirements. Also, these therapies have shown better responses and help patients get longer remissions.

Key Insights

• As per the analysis shared by our research analyst, the global tumor-infiltrating lymphocyte (TIL) therapy market size is estimated to grow annually at a CAGR of around 28.60% over the forecast period (2025-2034).
• In terms of revenue, the global tumor-infiltrating lymphocyte (TIL) therapy market size was valued at around USD 289.56 million in 2024 and is projected to reach USD 3,582.19 million by 2034.
• Clinical and medical factors are driving the growth of the global tumor-infiltrating lymphocyte (TIL) therapy market.
• Based on the sources, the surgical tumor segment is growing at a high rate and is projected to dominate the global market.
• Based on indications, the solid tumor segment is anticipated to grow with the highest CAGR in the global market.
• Based on the therapy types, the autologous therapy segment is projected to swipe the largest market share.
• Based on region, North America is expected to dominate the global market during the forecast period.

Tumor-Infiltrating Lymphocyte (TIL) Therapy Market: Growth Drivers

• Clinical and medical factors are likely to drive the growth of the global market.

TIL therapy is proven to have better objective response rates, particularly for lung and cervical cancer. Also, the durability of the response to these therapies is long-lasting. These help patients with late-stage cancer, and therefore, people find these therapies attractive than other conventional therapies.

Clinical trials for these therapies are expanding, which is broadening the global tumor-infiltrating lymphocyte (TIL) therapy market's potential. Medical companies are combining TILs with different immune checkpoint inhibitors, which is further expected to revolutionize the market by improving the efficiency and efficacy of the outcomes.

However, the favorable regulatory landscape is also emerging as a key driver of the industry's growth. Approval of Lifileucel by the FDA is a market benchmark actively used in treating patients. Governments worldwide have accelerated the approval pathways, which is likely to support the industry's growth.

For instance, Researchers from some leading cancer institutes revealed significant development in 2024  in the growth and function of TILs. This development is likely to enhance the efficiency and accessibility of TIL therapies for patients with cancer.

Tumor-Infiltrating Lymphocyte (TIL) Therapy Market: Restraints

• Cost-intensive manufacturing is likely to hinder the growth of the market.

Autologous therapy requires personalized manufacturing, increasing production timelines and operational costs. Also, it forces the need for good manufacturing practice facilities, which limits its capability and accessibility in the tumor-infiltrating lymphocyte (TIL) therapy industry, particularly in developing and underdeveloped countries. Also, the extraction process is too long, which will likely restrict patients with a disease that is progressing further.

Tumor-Infiltrating Lymphocyte (TIL) Therapy Market: Opportunities

• Technological advancements are likely to foster growth opportunities in the global market.

Advancements and expansion are among the major factors driving growth opportunities in the global tumor-infiltrating lymphocyte (TIL) therapy market. Manufacturers have developed closed-system bioreactors and AI-optimized cultural media to eliminate the risk of infection and improve the therapy's outcome.

Additionally, all the leading companies across the globe are contributing to good manufacturing practice facilities, which is likely to revolutionize the market. Moreover, automation and standardization are emerging as major factors in improving scalability and lowering production costs. Significant investments from venture capital are likely to fuel trials and innovations in the market. Mergers and acquisitions of major biotech and pharma companies are anticipated to bring new technologies into the mainstream market.

Furthermore, rising patient awareness of the availability of personalized immunotherapy options will likely drive the market's growth manifold in the coming years. For instance, the FDA approved a new therapy for advanced melanoma in 2024. It is an effective treatment for metastatic melanoma in patients.

Tumor-Infiltrating Lymphocyte (TIL) Therapy Market: Challenges

• Limited commercialization is a big challenge in the global market.

There are not enough TILs available in the market, which is emerging as a big challenge in the tumor-infiltrating lymphocyte (TIL) therapy industry. Many therapies are still in the approval process; thus, their commercialization is still pending. They need better infrastructure and technical labs, which are also likely to negatively influence the industry's growth.

Report Scope

Tumor-Infiltrating Lymphocyte (TIL) Therapy Market: Segmentation

The global tumor-infiltrating lymphocyte (TIL) therapy market can be segmented into sources, indications, therapy types, and regions.

Based on the sources, the market can be segmented into blood and surgical tumor samples. The surgical tumor samples segment is expected to account for the largest share of the tumor-infiltrating lymphocyte (TIL) therapy industry during the forecast period. These samples offer a better environment than blood samples for lymphocytes. These lymphocytes have better therapy effectiveness as they have already encountered tumor antigens and have more potential to fight against cancer cells. These tumors have better specificity that can help improve the therapeutic outcomes.

Also, these have high clinical success rates, helping TIL therapies expand. Additionally, the standard protocols for extracting TIL from tumor tissues are further likely to boost the growth of the segment. Additionally, these samples facilitate faster treatment, as they undergo a quick expansion process in the lab. Tumor tissues also help offer more viable lymphocytes than blood samples.

Furthermore, these have better regulatory approval processes because of their demonstrated efficacy. Therefore, all these factors are expected to foster growth in the global market.

On the basis of indications, the market can be segmented into hematological malignancies, solid tumors, and others. A solid tumor is the fastest-growing segment in the global tumor-infiltrating lymphocyte (TIL) therapy market during the forecast period. Solid tumors are likely to show remarkable effectiveness in the treatment of patients with melanoma.

Moreover, these have high clinical success rates due to the availability of better TIL therapies. The approval of immunotherapy by Loveland Biotherapeutics marks a significant milestone in the history of cancer treatment, likely to revolutionize the market in the years to come.

Also, these therapies easily satisfy the requirements of modern treatment parameters, which remain unmet in traditional therapies like radiation or chemotherapy. Additionally, these are personalized approaches that have a better chance of remission.

However, the strong pipeline of TIL therapies in solid tumor trials is also likely to positively influence the growth of the segment. Many of the trial therapies for TIL are in phases 2 and 3, which are likely to further foster developments in the segment. These trials are largely for cervical cancer, breast cancer, and melanoma. Moreover, many giant companies are investing in TILs for solid tumors, which is expected to further contribute to the significant rise of the segment.

On the basis of therapy types, the market can be segmented into allogeneic therapy and autologous therapy. The autologous TIL therapy segment is expected to dominate the tumor-infiltrating lymphocyte (TIL) therapy industry during the forecast period. It utilizes the patient's own tumor in order to let it expand in the external environment and thereafter be reinfused into the patient's body. This process has a very high chance of targeting and less risk of immune rejection as these cells are patient-specific.

Additionally, autologous therapy has been the most successful clinical trial to date, particularly in the fields of cervical cancer and melanoma, which is a crucial factor contributing to the high growth of the segment. These are low-risk therapy, which almost eliminates the risk of GvHD. Phototherapy is highly favored in personalized cancer treatment because it is more specific than generalized. Also, the automated manufacturing platforms can easily scale autologous therapy in a shorter period at an affordable cost.

Tumor-Infiltrating Lymphocyte (TIL) Therapy Market: Regional Analysis

• North America to dominate the global market.

North America accounts for the largest share of the global tumor-infiltrating lymphocyte (TIL) therapy market during the period. The US is the leading market in North America because of the rapidly growing development and commercialization of TIL therapies. However, the rising cases of melanoma, cervical cancer, and lung cancer are further expected to foster developments in the regional market.

Also, the ongoing approval of TILs by the FDA is expected to drive the regional market's growth. The increasing biotech investments in the US are also likely to widen the scope of the regional market. The presence of an advanced R&D ecosystem in the United States, particularly for TIL-based therapies, is likely to revolutionize the market. Canada also contributes a modest share of the North American market. The government in the region is encouraging many oncology programs, which are likely to accelerate the growth of the Canadian market.

However, the rapidly growing public healthcare infrastructure is also a major reason for the high growth rate of the regional market. Pharmaceutical institutions are engaging in collaborative research, which is likely to contribute to the development of many immunotherapies on the market in the coming years. Therefore, North America is expected to witness spectacular CAGR growth during the forecast period.

Asia Pacific is also projected to witness a significant rise in sales revenue for the regional market in the coming years. APAC is facing a rising number of cancer incidences, like cervical cancer, lung cancer, and melanoma. However, government initiatives to invest in biotechnology and healthcare infrastructure are facilitating a high growth rate in the regional market, thereby easing the healthcare burden in the region. China is a leading market in the region because of the high government support.

Moreover, companies in the region are developing more innovative TIL therapies that are likely to revolutionize the market further. Japan is known for its advanced healthcare infrastructure, which is likely to positively influence the growth of the APAC market.

Tumor-Infiltrating Lymphocyte (TIL) Therapy Market: Competitive Analysis

The key players in the global tumor-infiltrating lymphocyte (TIL) therapy market include:

• Prometheus Laboratories
• Incyte Corporation
• CAR-T (Shanghai) Cell Biotechnology
• Lytix Biopharma
• Instil Bio
• Bristol-Myers Squibb
• Iovance Biotherapeutics

For instance, Biotech Cos entered a partnership in 2024 to generate data for TIL therapy. This collaboration is likely to bring more data insights into TIL therapies. The task is to focus on developing next-generation TIL therapies and a combination of treatments, including immunotherapy.

The global tumor-infiltrating lymphocyte (TIL) therapy market is segmented as follows:

By Sources Segment Analysis

• Blood Samples
• Surgical Tumor Samples

By Indications Segment Analysis

• Hematological Malignancies
• Solid Tumors
• Others

By Therapy Types Segment Analysis

• Allogeneic Therapy
• Autologous Therapy

By Regional Segment Analysis

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America